Please ensure Javascript is enabled for purposes of website accessibility

Alabama Legalizes Medical Cannabis: Which Pot Stocks Could Benefit?

By Eric Volkman - Updated Jun 23, 2021 at 9:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A Deep South state flips the switch on doctor-prescribed weed; it's possible a well-known pot company in neighboring Florida will take an interest in the market.

Months after the so-called "green wave" of states legalizing marijuana to some extent on Election Day 2020, more are flipping the switch. One of the more recent is Alabama, located squarely in a region formerly known for its unwillingness to liberalize cannabis laws.

In this clip from Motley Fool Live, recorded on May 21, veteran Fool contributor Eric Volkman talks to healthcare and cannabis bureau chief Corinne Cardina about why and how Alabama has opened its medical marijuana market, and speculates about one notable marijuana company that might be interested in opening for business there.

Corinne Cardina: Moving further down south. This week, the governor of Alabama signed a law that legalizing medical marijuana use in this state, making certain kinds of cannabis legal for registered patients with qualifying conditions.

A lot of restrictions to be aware of here, first being that this law does not even allow smoking, vaping, or consuming medical marijuana in baked products. A little bit unclear on that, but what they are allowing is consuming medical cannabis as tablets, capsules, gummies, lozenges, topicals, suppositories, transdermal patches, and in nebulizers or as vaporized oil.

This continues the trend of Southern states liberalizing cannabis laws, even a small step at a time. Mississippi residents voted to open a medical cannabis market back in November as part of our green wave that we saw. Even in Virginia, marijuana possession of up to an ounce for adults 21 and up will become legal this summer.

Eric, can you help me make sense of what exactly this medical cannabis market is going to look like and what the rationale is as well?

Eric Volkman: It's strange, isn't it? I mean, there's this whole weird laundry list of somewhat obscure ways of consuming cannabis. Honestly, if somebody has a medical need for cannabis, let them consume in any way they want, who cares?

The thing is, we have to put it in context. Like you say, Southern states have been relatively recent, and kind of slow and incremental, to legalize. This isn't entirely unexpected, and it does represent a big step forward because formerly, states in that part of the country were quite against any kind of legalization -- be it recreational or medical.

I'm sure at some point the market [regulations] will get looser. I mean, is anybody, are the state revenue authorities or are patients, being served by this six pages of restrictions? I don't think so. Once they see that the program is working and people are getting the medicines that they need, I think they are going to be a little bit less restrictive.

In the context of wider American legalization, [Alabama] is a good development. As for a market in and of itself, I don't think it's going to be such a big target for anyone. Again, consider that it's medical marijuana only being legalized. For obvious reasons, it's a very constricted market and very limited. Recreational is not on the table as far as we know. I think in some ways, given the politics, they were lucky to get this far.

I think for any nationwide companies, I don't think they're going to make Alabama a priority. One exception maybe, kinda, sorta, perhaps, will be Trulieve Cannabis (TCNNF 1.23%), which is based in neighboring Florida, and they might like the chance to jump quickly and easily into a neighboring state. But at this point that's only rampant speculation. Trulieve, as we'll see, likes the idea of expanding. But we don't know.

It's still very early with Alabama's legalization and we don't quite know how exactly it's going to shape up. There's an Alabama Medical Cannabis Commission, which like the New York General Marijuana Commission, is going to be establishing rules and parameters of licensing. They've been tasked to start medical cannabis retail licensing. They have over a year to do it, which sounds like an awful lot [of time] to me. They have to get it done by Sept. 1. They have to at least start the licensing process by then.

Cardina: Sept. 1 of next year.

Volkman: Next year, sorry, 2022. That's the broad strokes of what we know. We're still not sure of what the rules are going to be, the compliance, the regulations. Whether outside entities will be able to enter or whether it would be in some way limited to local companies. So there are a lot of question marks. But if you're going to keep an eye on it, if any company were to jump in, I would suspect Trulieve.

Corinne Cardina has no position in any of the stocks mentioned. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Trulieve Cannabis Corp. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trulieve Cannabis Stock Quote
Trulieve Cannabis
TCNNF
$13.15 (1.23%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.